- Home
- AVDX vs GERN Comparison
AVDX vs GERN Comparison
Compare AVDX & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVDX
- GERN
- Stock Information
- Founded
- AVDX 2000
- GERN 1990
- Country
- AVDX United States
- GERN United States
- Employees
- AVDX N/A
- GERN N/A
- Industry
- AVDX EDP Services
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- AVDX Technology
- GERN Health Care
- Exchange
- AVDX Nasdaq
- GERN Nasdaq
- Market Cap
- AVDX 1.6B
- GERN 1.5B
- IPO Year
- AVDX 2021
- GERN 1996
- Fundamental
- Price
- AVDX $8.52
- GERN $1.48
- Analyst Decision
- AVDX Hold
- GERN Buy
- Analyst Count
- AVDX 15
- GERN 11
- Target Price
- AVDX $9.79
- GERN $5.80
- AVG Volume (30 Days)
- AVDX 2.2M
- GERN 15.1M
- Earning Date
- AVDX 05-07-2025
- GERN 05-01-2025
- Dividend Yield
- AVDX N/A
- GERN N/A
- EPS Growth
- AVDX N/A
- GERN N/A
- EPS
- AVDX 0.04
- GERN N/A
- Revenue
- AVDX $438,940,000.00
- GERN $76,994,000.00
- Revenue This Year
- AVDX $6.41
- GERN $208.83
- Revenue Next Year
- AVDX $10.70
- GERN $57.49
- P/E Ratio
- AVDX $216.09
- GERN N/A
- Revenue Growth
- AVDX 15.29
- GERN 32386.92
- 52 Week Low
- AVDX $6.61
- GERN $1.46
- 52 Week High
- AVDX $12.93
- GERN $5.34
- Technical
- Relative Strength Index (RSI)
- AVDX 52.06
- GERN 28.23
- Support Level
- AVDX $8.22
- GERN $1.63
- Resistance Level
- AVDX $8.78
- GERN $1.89
- Average True Range (ATR)
- AVDX 0.39
- GERN 0.11
- MACD
- AVDX 0.13
- GERN 0.02
- Stochastic Oscillator
- AVDX 88.05
- GERN 6.82
About AVDX AvidXchange Holdings Inc.
AvidXchange Holdings Inc is a provider of AP automation software and payment solutions for middle-market businesses and their suppliers. It generates the majority of its sales from Payment revenue followed by Software revenue and Services revenue. The company generates revenue in the United States.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.